Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma >BMY BLUE
Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma >BMY BLUE
DJ Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma >BMY BLUE
By Colin Kellaher
Bristol Myers Squibb Co. and bluebird bio Inc. said the U.S. Food and Drug Administration approved Abecma for the treatment of adults with the blood cancer multiple myeloma.
The companies said the approval covers the CAR T cell immunotherapy formerly known as idecabtagene vicleucel, or ide-cel, for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
New York-based Bristol Myers and bluebird, a Cambridge, Mass., biotechnology company, are jointly developing and commercializing Abecma in the U.S. For bluebird, the FDA nod marks its first approved treatment in oncology and first approved treatment in the U.S.
Shares of bluebird, which closed Friday at $29.98, rose more than 9% in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 29, 2021 07:23 ET (11:23 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma >BMY BLUE
DJ百时美施贵宝，蓝鸟获得FDA批准用于Abecma多发性骨髓瘤>BMY蓝
By Colin Kellaher
科林·凯莱赫(Colin Kellaher)著
Bristol Myers Squibb Co. and bluebird bio Inc. said the U.S. Food and Drug Administration approved Abecma for the treatment of adults with the blood cancer multiple myeloma.
百时美施贵宝公司(Bristol Myers Squibb Co.)和蓝鸟生物公司(Bluebird Bio Inc.)表示，美国食品和药物管理局(FDA)批准阿贝玛用于治疗成人血癌多发性骨髓瘤。
The companies said the approval covers the CAR T cell immunotherapy formerly known as idecabtagene vicleucel, or ide-cel, for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
两家公司表示，批准范围包括CAR T细胞免疫疗法，前身为idecabtagene vicleucel，或ide-cel，适用于经过四种或四种以上先前治疗后复发或难治性多发性骨髓瘤的成年人。
New York-based Bristol Myers and bluebird, a Cambridge, Mass., biotechnology company, are jointly developing and commercializing Abecma in the U.S. For bluebird, the FDA nod marks its first approved treatment in oncology and first approved treatment in the U.S.
总部设在纽约的百时美施贵宝公司和位于马萨诸塞州剑桥市的生物技术公司Bluebird正在美国联合开发Abecma并将其商业化。FDA的认可标志着该公司首次在肿瘤学领域获得批准，也是第一次在美国获得批准的治疗方法。
Shares of bluebird, which closed Friday at $29.98, rose more than 9% in premarket trading Monday.
蓝鸟的股价在周一盘前交易中上涨超过9%，上周五收于29.98美元。
Write to Colin Kellaher at colin.kellaher@wsj.com
写信给Colin Kellaher，电子邮件：colin.kellaher@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
March 29, 2021 07:23 ET (11:23 GMT)
2021年3月29日东部时间07：23(格林尼治标准时间11：23)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧